Financial Data and Key Metrics Changes - Q1 2025 revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [19][30] - Non-GAAP EPS was $0.97, at the high end of guidance [18][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [24] - Non-GAAP operating margin was 20.4% in Q1 [27] - Cash flow from operations was $240 million, with free cash flow at $208 million [28] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [19] - Sequencing instruments revenue was approximately flat at $109 million [22] - Sequencing service and other revenue decreased by approximately 5% year over year to $142 million [23] Market Data and Key Metrics Changes - Clinical business consumables grew mid-single digits, while research consumables were down in the high mid to high single-digit range [49] - The Greater China region is expected to contribute only $165 million to $185 million in full-year revenue, significantly down from previous levels [30][32] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [8][10] - A $100 million cost reduction program was initiated to address challenges in China and the U.S. funding environment [11][25] - The company is focused on advancing its Multiomics ecosystem and has several new product launches planned for 2025 and 2026 [13][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but emphasized the resilience of the business and strong sequencing activity [6][44] - The company is actively engaging with regulatory authorities in China to find long-term solutions [10][32] - Management expressed confidence in the long-term growth trajectory despite current headwinds [9][39] Other Important Information - The company is revising its guidance to reflect geopolitical impacts, particularly in China [29] - The estimated gross cost of tariffs for 2025 is approximately $85 million, impacting margins [34][35] Q&A Session Summary Question: What is the outlook for revenue growth and margins? - Management believes revenue growth will rebound and margins will expand above 25% in the future, with a focus on cost control [41][42] Question: What are the growth rates for clinical and research segments? - Clinical revenue grew mid-single digits, while research revenue is expected to decline in the mid-double digits for the remainder of the year [49][50] Question: How are tariffs affecting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [66][68] Question: What is the impact of China on future revenue? - The company expects continued revenue decline from China, with proactive measures in place to mitigate risks [96]

Investors: Brian Blanchett +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 | | | | GAAP | | | | Non-GAAP (a) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Dollars in millions, except per share amounts | | Q1 2025 | | Q1 2024 | | Q1 2025 | | Q1 2024 | | Revenue (b) | $ | 1,041 | $ | 1,056 | $ | 1,041 | $ | 1,056 | | Gross margin (c) | | 65.6 % | | 65.7 % | | 67.4 % | | 67.1 % | | Research and de ...

Core Insights - The company reported a revenue of 3.013 billion yuan for 2024, representing a year-on-year growth of 3.48% [1] - The net profit attributable to shareholders was -601 million yuan, with a year-on-year increase of 1.10% [1] - The first quarter of 2025 saw a revenue decline of 14.26% year-on-year, amounting to 455 million yuan [1] Financial Performance - In Q4 2024, the company achieved a revenue of 1.143 billion yuan, a significant year-on-year increase of 61.64% [1] - The gross profit margin for 2024 was 55.51%, down 3.96 percentage points from the previous year [2] - The net profit margin was -20.22%, showing a slight improvement of 0.64 percentage points year-on-year [2] Business Segments - The core sequencing business generated 2.348 billion yuan in revenue, with a year-on-year growth of 2.47% [3] - The company sold nearly 1,270 new sequencing instruments in 2024, marking a 48.59% increase year-on-year [3] - The laboratory automation segment achieved a revenue of 209 million yuan, with a year-on-year growth of 36.69% after excluding pandemic-related revenues [4] Market Position and Strategy - The company holds a global market share of approximately 7.1% in revenue terms and 28.2% in terms of new sales installations [3] - The domestic market share for new instrument installations reached about 63.8%, with revenue market share increasing to 39% [3] - The company is accelerating its global expansion with nearly 900 overseas marketing personnel [3] Future Outlook - Revenue projections for 2025-2027 are set at 3.607 billion, 4.500 billion, and 5.597 billion yuan, reflecting year-on-year growth rates of 20%, 25%, and 24% respectively [5] - The net profit forecast for 2025 is -177 million yuan, with a significant turnaround expected by 2027, reaching 182 million yuan [5] - The company is positioned as a leading domestic sequencing instrument provider, with potential for further market share growth due to ongoing product innovations and geopolitical factors [5]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $40.8 million, a decrease of 10% year-over-year, attributed to a challenging market environment and elevated backlog from the previous year [9][29] - Non-GAAP gross margins were 53.2%, down from 56.2% in Q1 2024, impacted by lower volume and price realization [32] - The net loss for the quarter was $26 million, an improvement from a net loss of $32.2 million in Q1 2024, representing a 19% improvement [34] - Adjusted EBITDA loss improved to $16.9 million from $23.7 million year-over-year, a 29% improvement [34] Business Line Data and Key Metrics Changes - Consumables revenue was $14.5 million, down 16% year-over-year, primarily due to lower volumes in the Americas Academia segment [29][30] - Instruments revenue increased by 24% year-over-year to $7.8 million, driven by strong demand for spatial proteomics products [30][32] - Services revenue, including lab and field services, was $17.6 million, down 16% year-over-year, with lab services declining by 19% due to backlog gaps [31][32] Market Data and Key Metrics Changes - The Americas market is experiencing a mid-teens percentage decline in academic revenue, with a high single-digit million dollar impact expected [10][36] - International markets and biopharma engagement remain resilient, with continued traction noted in these segments [10][11] Company Strategy and Development Direction - The company is focused on high precision proteomics and expanding its distributed offerings through partnerships, particularly with Illumina [25][66] - A disciplined M&A strategy is in place, with a focus on consolidating the market and leveraging operational synergies [26][48] - The company aims to reach adjusted EBITDA positive by 2026 while maintaining a healthy cash position of $261 million with no material debt [13][35] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic operating environment but emphasizes a strong internal position with a diversified portfolio and disciplined operating model [8][14] - The company expects the second half of 2025 to be back-weighted in terms of revenue, driven by larger projects in the sales funnel [42][36] - Management remains cautious about the impact of tariffs and macroeconomic conditions but believes they can manage these challenges effectively [11][36] Other Important Information - The company has operationalized $90 million in annualized cost reductions since the merger with SomaLogic, which is crucial for navigating current uncertainties [33] - New product launches at the AACR conference included three new offerings aimed at enhancing the company's market position in proteomics [19][20] Q&A Session Summary Question: Guidance on revenue weighting for 2025 - Management indicated that the revenue is expected to be back half weighted, driven by larger projects in the sales funnel [42] Question: Instrument demand and sales funnel outlook - Management expressed encouragement regarding growth in the sales funnel, particularly for the Hyperion XTI, but refrained from declaring victory due to market uncertainties [43][44] Question: Update on U.S. Academic and government demand - Management confirmed a mid-teens decline in U.S. Academic revenue, with some delays in consumables orders due to funding uncertainties [51][54] Question: Feedback on new product launches - Management noted that the new single soma reagents are now fully available, with expectations for significant long-term opportunities despite initial cautious sales expectations [60][62] Question: Illumina partnership revenue expectations - Management is optimistic about the long-term potential of the Illumina partnership but cautioned that significant revenue growth is not expected in 2025 [65][68] Question: Biopharmaceutical market conditions - Management reported good traction in the biopharma sector, with healthy growth in the sales funnel beyond large customers [69] Question: Impact of cost reduction actions on EBITDA outlook - Management indicated that the recent cost reduction actions would contribute to an improved outlook for adjusted EBITDA losses [70]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to benefit from domestic substitution and AI sequencing, leading to increased demand [1] - The company's revenue for 2024 is projected to be 3.013 billion yuan, with a year-on-year growth of 3.48%, while the net profit attributable to the parent company is expected to be -600.83 million yuan, indicating a reduction in losses [1] - The company has a strong competitive position as the only domestic and one of the few global full-product sequencing instrument manufacturers [1] Financial Performance Summary - Total revenue for 2023 is 2.911 billion yuan, with a year-on-year decline of 31.19% [1] - For 2024, the revenue is expected to increase to 3.013 billion yuan, with a projected growth of 24.66% in 2025, reaching 3.756 billion yuan [1] - The net profit for 2024 is forecasted at -600.83 million yuan, improving to -170.21 million yuan in 2025, and turning positive in 2026 with a net profit of 100.09 million yuan [1] - The earnings per share (EPS) is expected to improve from -1.46 yuan in 2023 to -1.44 yuan in 2024, and then to -0.41 yuan in 2025 [1] Business Segment Performance - The gene sequencing instrument business is expected to maintain high growth, with revenue of 2.348 billion yuan in 2024, a year-on-year increase of 2.5% [1] - Domestic revenue for the gene sequencing instrument business is projected to be 1.607 billion yuan, reflecting an increase of 11.4%, while overseas revenue is expected to be 741 million yuan, a decrease of 12.7% [1] - The company has established nine global R&D centers and seven production bases, indicating a strong commitment to international expansion [1] Market Position and Strategy - The company has increased its market share in domestic sales of sequencing instruments to 63.8% in 2024, with a global market share of 28.2% [1] - The introduction of AI technology in products, such as the AIO intelligent control software, is expected to enhance sequencing efficiency and expand application scenarios [1] - The company is actively pursuing opportunities for domestic substitution, particularly as its main competitor, Illumina, faces limitations in the domestic market [1]

Group 1 - The core viewpoint of the article highlights BGI Genomics as a leading player in the biotechnology sector, particularly in gene sequencing, emphasizing its role in breaking international monopolies and establishing a technological moat in China [1][3] - BGI Genomics went public on the STAR Market in September 2022, with an initial share price of 87.18 yuan, achieving a market capitalization exceeding 42 billion yuan on its first trading day, making it one of the largest IPOs in the biotechnology sector that year [3] - As of the end of Q1 2024, BGI Genomics maintained a market capitalization of over 30 billion yuan, leading domestic competitors in gene sequencing equipment [3] Group 2 - BGI Genomics has achieved significant technological breakthroughs, notably with its DNBSEQ sequencing platform, which has reached international leading levels in sequencing accuracy and cost control [4] - The company has installed over 3,000 gene sequencing instruments globally, covering 85 countries, and has captured over 35% market share in China, positioning itself as a strong competitor to Illumina [4] - BGI Genomics holds over 2,400 patents, including more than 600 international PCT patents, establishing a comprehensive intellectual property system across the entire value chain [4] Group 3 - Following its IPO, BGI Genomics accelerated its global strategy, achieving CE certification for multiple devices in 2023 and becoming the first domestic sequencing instrument to receive FDA certification [6] - The company has enhanced its manufacturing capacity, with its Wuhan facility increasing annual production capacity to 2,000 units and achieving over 90% localization of core components [6] - BGI Genomics has formed a "Precision Medicine Alliance" with over 1,000 global research institutions and pharmaceutical companies, with overseas revenue accounting for 43% of total revenue in 2023 [6] Group 4 - BGI Genomics faces challenges including risks of technological iteration, supply chain security, and geopolitical pressures, necessitating a focus on local operational capabilities [8] - The company plans to allocate 30% of its fundraising towards the development of AI-assisted diagnostic systems and aims to establish regional centers in Southeast Asia and the Middle East to diversify market risks [8] Group 5 - The growth trajectory of BGI Genomics reflects a typical path for Chinese hard-tech companies, characterized by technological breakthroughs, capital support, and global competition [9] - The company is transitioning from domestic substitution to setting global standards in gene sequencing technology, which is seen as crucial for understanding human life codes [9]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to benefit from domestic substitution and AI sequencing, leading to increased demand [1] - The company's revenue for 2024 is projected at 3.013 billion yuan, with a year-on-year growth of 3.48%, while the net profit attributable to the parent company is expected to be a loss of 600.83 million yuan, a reduction in loss of 7 million yuan [8] - The company has a strong competitive position as the only domestic and one of the few global full-product sequencing instrument manufacturers [1] Financial Performance Summary - Total revenue for 2023 is reported at 2.911 billion yuan, with a year-on-year decline of 31.19% [1] - The company achieved a revenue of 11.43 billion yuan in Q4 2024, reflecting a significant increase of 61.64% [8] - The revenue from the gene sequencing instrument business in 2024 is expected to be 2.348 billion yuan, with a growth of 2.5% [8] - The company anticipates a revenue of 3.756 billion yuan in 2025, representing a growth of 24.66% [1] Market Position and Strategy - The company has established nine global R&D centers, seven production bases, and thirteen customer experience centers, indicating a robust international presence [8] - The domestic market share for newly sold sequencing instruments reached 63.8% in 2024, while the global market share was 28.2% [8] - The company is actively pursuing opportunities for domestic substitution, particularly as its main competitor faces limitations in the domestic market [1]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Akoya Biosciences, driven by higher revenues, but actual results compared to estimates will significantly influence stock price movements [1][2]. Financial Expectations - Akoya is expected to report a quarterly loss of $0.29 per share, reflecting a year-over-year change of +17.1% [3]. - Revenues are projected to be $19.88 million, which is an increase of 8.3% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate for Akoya has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Akoya is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +20.69%, suggesting a more optimistic outlook from analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. - However, Akoya currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Akoya was expected to post a loss of $0.15 per share but actually reported a loss of $0.17, resulting in a surprise of -13.33% [12]. - Over the past four quarters, Akoya has only beaten consensus EPS estimates once [13]. Industry Comparison - Illumina, another player in the biomedical and genetics industry, is expected to report earnings of $0.96 per share, showing a year-over-year change of +966.7%, with revenues projected at $1.04 billion, down 3.5% from the previous year [17]. - Illumina's consensus EPS estimate has been revised 0.6% lower in the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.18%, indicating a likelihood of beating the consensus EPS estimate [18].

Core Insights - Analysts forecast Illumina (ILMN) to report quarterly earnings of $0.96 per share, reflecting a year-over-year increase of 966.7% [1] - Expected revenues are projected at $1.04 billion, indicating a decline of 3.5% compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 0.6% in the past 30 days [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Breakdown - Analysts expect 'Revenue- Product revenue- Consumable' to be $763.09 million, showing a year-over-year change of +0.1% [5] - The estimate for 'Revenue- Service and other revenue' is $170.12 million, suggesting a decline of 14.9% year over year [5] - 'Revenue- Product revenue' is predicted to reach $872.04 million, indicating a decrease of 0.5% [5] Core Revenue Metrics - 'Revenues- Core Illumina- Service and other revenue' is expected to be $175.08 million, reflecting a year-over-year increase of 1.2% [6] - 'Revenues- Core Illumina- Total product revenue' is projected at $869.69 million, suggesting a decline of 1.5% year over year [6] Instrument and Consumable Revenue - 'Revenue- Product revenue- Instruments' is likely to be $108.95 million, indicating a change of -4.4% from the prior-year quarter [7] - 'Revenues- Core Illumina- Consumables' is expected to reach $748.87 million, reflecting a decrease of 2.6% [7] Sequencing Revenue Estimates - 'Revenue- Sequencing- Instruments' is projected at $108.51 million, indicating a change of -1.4% from the year-ago quarter [8] - 'Revenue- Sequencing- Consumables' is expected to be $679.85 million, suggesting a decline of 2.6% year over year [8] Microarrays Revenue Forecast - 'Revenue- Microarrays- Instruments' is estimated to reach $3.61 million, indicating a change of -9.9% from the prior-year quarter [9] - 'Revenue- Microarrays- Consumables' is projected at $74.59 million, reflecting a year-over-year change of +5.1% [9] - Overall, 'Revenue- Core Illumina' is expected to be $1.03 billion, indicating a decline of 2.1% year over year [9] Stock Performance - Illumina shares have returned +5% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [9] - With a Zacks Rank 3 (Hold), ILMN is expected to mirror the overall market performance in the near future [10]

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapiesDataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapiesSAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially av ...